James T. Thigpen, MD, discusses the comparison of treatment options in ovarian cancer.
James T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the comparison of treatment options in ovarian cancer.
Clinical Pearls
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More